Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.

Ther Adv Hematol · 2016 · PMC5026292 · PMID 27695618

Europe PMC DOI

hedged sentence

0.0257

closest p · 0.5× alpha

0.0257

boldest claim

The sentences

a strong trendp = 0.0257actually significant

An interim analysis of overall survival (OS) revealed a HR of 0.77 (95% CI 0.61–0.97) indicating a strong trend ( p = 0.0257) for treatment with E-L/d versus L/d [ Dimopoulos, 2015 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.